Kinarus Therapeutics Holding AG
SIX:KNRS

Watchlist Manager
Kinarus Therapeutics Holding AG Logo
Kinarus Therapeutics Holding AG
SIX:KNRS
Watchlist
Price: 15 CHF 416 566.67%
Market Cap: 19.5B CHF
Have any thoughts about
Kinarus Therapeutics Holding AG?
Write Note

Kinarus Therapeutics Holding AG
Net Issuance of Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Kinarus Therapeutics Holding AG
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
Kinarus Therapeutics Holding AG
SIX:KNRS
Net Issuance of Debt
CHf520k
CAGR 3-Years
0%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Wizz Air Holdings PLC
LSE:WIZZ
Net Issuance of Debt
-€845.9m
CAGR 3-Years
N/A
CAGR 5-Years
-28%
CAGR 10-Years
N/A
No Stocks Found

Kinarus Therapeutics Holding AG
Glance View

Market Cap
19.5B CHF
Industry
Airlines

Kinarus Therapeutics Holding AG is a Swiss biopharmaceutical company at the forefront of innovative drug development, particularly in the realm of advanced therapies for respiratory and viral diseases. Founded with the mission to address significant unmet medical needs, Kinarus is pioneering the use of its proprietary therapeutic platform that targets mechanisms associated with chronic and infectious conditions. The company is making strides with its lead candidate, KIN001, a novel treatment designed to combat COVID-19 while also addressing the long-term implications of the disease, illustrating Kinarus’s commitment to not only responding to immediate health crises but also improving patient outcomes over the long term. Investors will find Kinarus's strategic focus compelling, as it centers on leveraging its unique drug candidates to tap into lucrative markets with expansive potential for growth. The company collaborates with academic institutions and industry partners, reinforcing its innovative edge and enhancing its research capabilities. Positioned in the robust European biotechnology landscape and with a skilled leadership team that emphasizes sustainable development, Kinarus stands out as an attractive investment opportunity for those looking to engage in the life sciences sector. Through its advancements, Kinarus aims to deliver both breakthrough therapies and significant shareholder value, making it a noteworthy player in the ever-evolving healthcare market.

KNRS Intrinsic Value
Not Available

See Also

What is Kinarus Therapeutics Holding AG's Net Issuance of Debt?
Net Issuance of Debt
520k CHF

Based on the financial report for Dec 31, 2023, Kinarus Therapeutics Holding AG's Net Issuance of Debt amounts to 520k CHF.

What is Kinarus Therapeutics Holding AG's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 5Y
29%

Over the last year, the Net Issuance of Debt growth was 73%.

Back to Top